PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICI) targeting programmed cell death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have greatly improved the clinical outcome in non-small cell lung cancer (NSCLC) patients [1,2,3].